secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0000950103-24-001047
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics grants Redmile preemptive rights up to 20% ownership threshold
-------------------------------------------------------------------------------

- Agreement preserves Redmile's preemptive and advance subscription rights if group holds ≤20% of share capital.
- If group exceeds 20%, board must find no change-of-control intent to keep rights intact; else rights may be restricted.
- Redmile caps aggregate voting rights at 15% of share capital unless otherwise mutually agreed.
- Agreement terminates upon removal of 20% clauses, 5 years if ownership <20%, redomiciliation, >30% ownership, or change-of-control finding.
- Redmile currently owns ~18.93% of shares and has confirmed no present intention to effect a change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324001047/0000950103-24-001047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324001047/dp205528_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-001047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer